A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Toshihiko DoiKei MuroHiroshi IshiiTerufumi KatoTakahiro TsushimaMitsuhiro TakenoyamaSatoshi OizumiKazuto GemmotoHideaki SunaKouki EnokitaniTetsuyoshi KawakamiHiroyoshi NishikawaNoboru YamamotoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Combining an anti-PD-1 antibody, nivolumab, with a Treg-depleting anti-CCR4 antibody, mogamulizumab, provides an acceptable safety profile, antitumor activity, and a potentially effective option in cancer immunotherapy.